Leerink Partnrs Has Pessimistic View of INSP FY2027 Earnings

Key Points

• Leerink Partners has downgraded its earnings per share estimate for Inspire Medical Systems for FY2027 to $2.34, decreasing from the previous estimate of $2.68.
• Inspire Medical Systems reported earnings of $0.45 EPS for the latest quarter, significantly surpassing the consensus estimate of $0.22 EPS, and demonstrating a year-over-year revenue increase of 10.8%.
• The company has received mixed ratings from analysts, with seven ratings as Buy, seven as Hold, and one as Sell, while the average price target sits at $148.00.

Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) - Stock analysts at Leerink Partnrs dropped their FY2027 earnings per share estimates for shares of Inspire Medical Systems in a research note issued on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now forecasts that the company will earn $2.34 per share for the year, down from their previous estimate of $2.68. The consensus estimate for Inspire Medical Systems' current full-year earnings is $2.16 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems' FY2028 earnings at $3.61 EPS.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.23. The business had revenue of $217.09 million for the quarter, compared to analysts' expectations of $214.50 million. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%.The firm's quarterly revenue was up 10.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.32 EPS. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS.

Other equities research analysts have also issued reports about the stock. Evercore ISI decreased their target price on shares of Inspire Medical Systems from $150.00 to $125.00 and set an "outperform" rating for the company in a research note on Tuesday, October 7th. UBS Group set a $89.00 target price on shares of Inspire Medical Systems and gave the company a "neutral" rating in a research note on Monday, September 22nd. Stifel Nicolaus set a $140.00 target price on shares of Inspire Medical Systems and gave the company a "hold" rating in a research note on Tuesday, August 5th. Royal Bank Of Canada reiterated an "outperform" rating and set a $150.00 target price on shares of Inspire Medical Systems in a research note on Friday, October 10th. Finally, Truist Financial reduced their price objective on Inspire Medical Systems from $125.00 to $90.00 and set a "hold" rating for the company in a research note on Wednesday. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $148.00.

Inspire Medical Systems Trading Up 0.1%

INSP stock opened at $78.92 on Thursday. The stock has a market capitalization of $2.33 billion, a PE ratio of 45.62, a price-to-earnings-growth ratio of 2.46 and a beta of 1.16. The stock's 50 day simple moving average is $82.86 and its 200 day simple moving average is $120.11. Inspire Medical Systems has a 12-month low of $70.77 and a 12-month high of $216.01.

Institutional Investors Weigh In On Inspire Medical Systems

A number of institutional investors have recently bought and sold shares of INSP. Quarry LP increased its stake in Inspire Medical Systems by 2,127.3% in the 1st quarter. Quarry LP now owns 245 shares of the company's stock worth $39,000 after buying an additional 234 shares in the last quarter. Banque Transatlantique SA bought a new position in shares of Inspire Medical Systems during the 1st quarter valued at about $46,000. Daiwa Securities Group Inc. boosted its holdings in shares of Inspire Medical Systems by 38.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company's stock valued at $60,000 after purchasing an additional 130 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Inspire Medical Systems by 27.2% during the 1st quarter. Smartleaf Asset Management LLC now owns 454 shares of the company's stock valued at $71,000 after purchasing an additional 97 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Inspire Medical Systems by 14.6% during the 2nd quarter. Farther Finance Advisors LLC now owns 603 shares of the company's stock valued at $78,000 after purchasing an additional 77 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company's stock.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, CFO Richard Buchholz sold 11,000 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $93.39, for a total value of $1,027,290.00. Following the completion of the sale, the chief financial officer owned 44,867 shares in the company, valued at approximately $4,190,129.13. This represents a 19.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 4.10% of the company's stock.

Inspire Medical Systems declared that its board has approved a stock repurchase plan on Monday, August 11th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to reacquire up to 8.6% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's leadership believes its shares are undervalued.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.